X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ITI-1001 is an investigational plasmid DNA vaccine therapy that leverages Immunomic’s proprietary UNITE® platform to treat patients with newly diagnosed GBM.
Lead Product(s): ITI-1001
Therapeutic Area: Oncology Product Name: ITI-1001
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
ITI-3000 is an anticancer vaccine made by combining LAMP1 (lysosomal-associated membrane protein) with the large T antigen of polyomavirus based on Immunomic's cell therapy vaccine platform UNITE.
Lead Product(s): ITI-3000
Therapeutic Area: Oncology Product Name: ITI-3000
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: PharmaJet
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
The collaboration will generate a novel product candidate derived from Lineage’s VAC allogeneic cancer immunotherapy platform and targeting a proprietary Tumor Associated Antigen (TAA) construct provided by ITI, for the treatment of glioblastoma multiforme (GBM).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: Lineage Cell Therapeutics
Deal Size: $69.0 million Upfront Cash: $2.0 million
Deal Type: Licensing Agreement April 20, 2021
Details:
ITI will employ CoImmune’s process for manufacturing and cGMP work for the advancement of ITI-1020, ITI’s autologous dendritic cell (DC) investigational vaccine loading with mRNA encoding LAMP: pp65 for the treatment of newly diagnosed glioblastoma (GBM).
Lead Product(s): ITI-1020
Therapeutic Area: Oncology Product Name: ITI-1020
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: CoImmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 19, 2020
Details:
Immunomic Therapeutics will present preclinical data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses when used with its investigational UNITE vaccine, ITI-3000, in mice.
Lead Product(s): ITI-3000
Therapeutic Area: Oncology Product Name: ITI-3000
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
ITI is developing several dendritic cell vaccines for the treatment of cancer, including ITI-1000 for glioblastoma (GBM) that contains pp65-shLAMP mRNA DCs with GM-CSF, a dendritic cell vaccines for the treatment of cancer.
Lead Product(s): ITI-1000,Tetanus and Diphtheria Toxoid vaccine
Therapeutic Area: Oncology Product Name: ITI-1000
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
ITI and Replicate will develop candidates combining ITI’s UNITE technology with Replicate’s scalable self-replicating RNA (SynRGY technology) for COVID-19, HPV, and EBV.
Lead Product(s): RBI-5000
Therapeutic Area: Infections and Infectious Diseases Product Name: RBI-5000
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Replicate Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 24, 2020
Details:
ITI will leverage Ichor’s TriGrid® Electroporation technology to increase cellular uptake of ITI-1001 when administered to patients with newly diagnosed Glioblastoma, or GBM.
Lead Product(s): ITI-1001
Therapeutic Area: Oncology Product Name: ITI-1001
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Ichor Medical Systems
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 16, 2020
Details:
ITI-3000 is an innovative and novel targeted approach to a MCPγV vaccine. This lysosomal targeting technology results in enhanced antigen presentation and a balanced T cell response, as ITI-3000 activated antigen-specific CD4+ T cells in vivo.
Lead Product(s): ITI-3000
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of its UNITE nucleic acid platform.
Lead Product(s): Dendritic cell vaccine therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: HLB
Deal Size: $61.3 million Upfront Cash: Undisclosed
Deal Type: Financing April 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
